Published in PLoS One on January 27, 2010
Global ovarian cancer health disparities. Gynecol Oncol (2012) 1.24
Assessment of hepatocyte growth factor in ovarian cancer mortality. Cancer Epidemiol Biomarkers Prev (2011) 1.14
Heme and FLVCR-related transporter families SLC48 and SLC49. Mol Aspects Med (2013) 0.86
Tumor-derived extracellular fragments of receptor protein tyrosine phosphatases (RPTPs) as cancer molecular diagnostic tools. Anticancer Agents Med Chem (2011) 0.81
It never rains but it pours: potential role of butyrophilins in inhibiting anti-tumor immune responses. Cell Cycle (2011) 0.79
The ontogeny of Butyrophilin-like (Btnl) 1 and Btnl6 in murine small intestine. Sci Rep (2016) 0.75
Altered expression of Butyrophilin (BTN) and BTN-like (BTNL) genes in intestinal inflammation and colon cancer. Immun Inflamm Dis (2016) 0.75
Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics (2004) 125.23
Global cancer statistics, 2002. CA Cancer J Clin (2005) 119.22
Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet (2006) 115.71
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 52.26
Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med (2000) 25.49
Score tests for association between traits and haplotypes when linkage phase is ambiguous. Am J Hum Genet (2001) 22.07
Selecting a maximally informative set of single-nucleotide polymorphisms for association analyses using linkage disequilibrium. Am J Hum Genet (2003) 21.52
Whole-genome patterns of common DNA variation in three human populations. Science (2005) 21.22
Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet (2005) 8.45
BeadArray technology: enabling an accurate, cost-effective approach to high-throughput genotyping. Biotechniques (2002) 5.98
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
Expression of msl-2 causes assembly of dosage compensation regulators on the X chromosomes and female lethality in Drosophila. Cell (1995) 3.49
A human protein complex homologous to the Drosophila MSL complex is responsible for the majority of histone H4 acetylation at lysine 16. Mol Cell Biol (2005) 3.04
Gene expression profiles predict early relapse in ovarian cancer after platinum-paclitaxel chemotherapy. Clin Cancer Res (2005) 2.29
Functional integration of the histone acetyltransferase MOF into the dosage compensation complex. EMBO J (2004) 1.93
Tagging single nucleotide polymorphisms in cell cycle control genes and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2007) 1.92
Consortium analysis of 7 candidate SNPs for ovarian cancer. Int J Cancer (2008) 1.82
Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol (2009) 1.61
Single nucleotide polymorphisms in the TP53 region and susceptibility to invasive epithelial ovarian cancer. Cancer Res (2009) 1.59
The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. Genome Res (2009) 1.52
Primary structure of a putative serine protease specific for IGF-binding proteins. FEBS Lett (1996) 1.46
Genetic variation in the one-carbon transfer pathway and ovarian cancer risk. Cancer Res (2008) 1.42
Progesterone receptor variation and risk of ovarian cancer is limited to the invasive endometrioid subtype: results from the Ovarian Cancer Association Consortium pooled analysis. Br J Cancer (2008) 1.38
Serine protease HtrA1 modulates chemotherapy-induced cytotoxicity. J Clin Invest (2006) 1.37
Contribution of BRCA1 and BRCA2 mutations to inherited ovarian cancer. Hum Mutat (2007) 1.33
Performance of amplified DNA in an Illumina GoldenGate BeadArray assay. Cancer Epidemiol Biomarkers Prev (2008) 1.32
The genetics of ovarian cancer. Best Pract Res Clin Obstet Gynaecol (2002) 1.32
Association of single nucleotide polymorphisms in glycosylation genes with risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (2008) 1.26
Estrogen bioactivation, genetic polymorphisms, and ovarian cancer. Cancer Epidemiol Biomarkers Prev (2005) 1.25
Independent test set performance in the prediction of early relapse in ovarian cancer with gene expression profiles. Clin Cancer Res (2005) 0.82
Genome-wide association study identifies novel breast cancer susceptibility loci. Nature (2007) 29.23
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1. Nat Genet (2008) 16.17
Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA (2010) 8.93
Genome partitioning of genetic variation for complex traits using common SNPs. Nat Genet (2011) 8.57
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nat Genet (2013) 8.24
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
A common coding variant in CASP8 is associated with breast cancer risk. Nat Genet (2007) 7.35
Control of BRCA2 cellular and clinical functions by a nuclear partner, PALB2. Mol Cell (2006) 7.33
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
Benign breast disease and the risk of breast cancer. N Engl J Med (2005) 6.84
Views of US physicians about controlling health care costs. JAMA (2013) 6.36
Genetic variation and cancer: improving the environment for publication of association studies. Cancer Epidemiol Biomarkers Prev (2004) 6.24
Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics. PLoS Genet (2008) 6.22
Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet (2008) 6.10
Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet (2009) 6.04
Dental x-rays and risk of meningioma. Cancer (2012) 5.99
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature (2008) 5.98
Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol (2002) 5.91
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case-control studies. Lancet Oncol (2012) 5.70
Three biomarkers identified from serum proteomic analysis for the detection of early stage ovarian cancer. Cancer Res (2004) 5.68
Parallel genotyping of over 10,000 SNPs using a one-primer assay on a high-density oligonucleotide array. Genome Res (2004) 5.59
Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58
Achieving a high-performance health care system with universal access: what the United States can learn from other countries. Ann Intern Med (2007) 5.25
A systematic genetic assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and BRCA2 breast cancer-predisposition genes. Am J Hum Genet (2007) 5.17
Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet (2009) 5.13
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Breast-cancer risk in families with mutations in PALB2. N Engl J Med (2014) 4.97
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. Nat Genet (2010) 4.96
Gene-panel sequencing and the prediction of breast-cancer risk. N Engl J Med (2015) 4.77
Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet (2004) 4.61
Associations of breast cancer risk factors with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium studies. J Natl Cancer Inst (2010) 4.54
The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet (2002) 4.54
Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet (2010) 4.51
FKBP51 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell (2009) 4.48
BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes. J Clin Oncol (2002) 4.38
A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet (2009) 4.38
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nat Genet (2013) 4.35
Trends in mastectomy rates at the Mayo Clinic Rochester: effect of surgical year and preoperative magnetic resonance imaging. J Clin Oncol (2009) 4.13
A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet (2010) 3.86
Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. JAMA (2012) 3.85
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol (2006) 3.73
RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. Am J Hum Genet (2007) 3.63
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. N Engl J Med (2003) 3.46
GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nat Genet (2013) 3.42